

Kiyotaka Yoh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/922730/publications.pdf>

Version: 2024-02-01

31
papers

1,639
citations

687363

13
h-index

434195

31
g-index

31
all docs

31
docs citations

31
times ranked

2430
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1655-1669. | 10.7 | 418 |
| 2 | Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 42-50. | 10.7 | 252 |
| 3 | Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1324-1331. | 1.1 | 150 |
| 4 | Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung. <i>Clinical Cancer Research</i> , 2017, 23, 757-765. | 7.0 | 144 |
| 5 | Mutational status of EGFR and KIT in thymoma and thymic carcinoma. <i>Lung Cancer</i> , 2008, 62, 316-320. | 2.0 | 97 |
| 6 | A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. <i>Lung Cancer</i> , 2016, 99, 186-193. | 2.0 | 88 |
| 7 | Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. <i>Cancer</i> , 2003, 98, 926-931. | 4.1 | 81 |
| 8 | A secondary RET mutation in the activation loop conferring resistance to vandetanib. <i>Nature Communications</i> , 2018, 9, 625. | 12.8 | 75 |
| 9 | Identification of a lung adenocarcinoma cell line with <i>CCDC6</i> RET fusion gene and the effect of RET inhibitors <i>in vitro</i> and <i>in vivo</i> . <i>Cancer Science</i> , 2013, 104, 896-903. | 3.9 | 67 |
| 10 | Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity. <i>Lung Cancer</i> , 2007, 55, 337-341. | 2.0 | 30 |
| 11 | High Body Mass Index Correlates with Increased Risk of Venous Irritation by Vinorelbine Infusion. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 206-209. | 1.3 | 29 |
| 12 | Severe Interstitial Lung Disease Associated with Amrubicin Treatment. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1435-1438. | 1.1 | 29 |
| 13 | First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 507-518. | 2.6 | 16 |
| 14 | Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 155, 40-45. | 2.0 | 15 |
| 15 | Docetaxel for platinum-refractory advanced thymic carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 665-669. | 1.3 | 14 |
| 16 | Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Lung Cancer</i> , 2021, 159, 128-134. | 2.0 | 13 |
| 17 | Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET). <i>Translational Lung Cancer Research</i> , 2021, 10, 314-325. | 2.8 | 13 |
| 18 | Phase I study of the irreversible fibroblast growth factor receptor 4 inhibitor futibatinib in Japanese patients with advanced solid tumors. <i>Cancer Science</i> , 2023, 114, 574-585. | 3.9 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 31-42. | 1.3 | 12 |
| 20 | A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer. <i>Investigational New Drugs</i> , 2020, 38, 1588-1597. | 2.6 | 12 |
| 21 | Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer. <i>Current Medical Research and Opinion</i> , 2020, 36, 1667-1675. | 1.9 | 11 |
| 22 | Predictive value of EGFR mutation in non-small cell lung cancer patients treated with platinum doublet postoperative chemotherapy. <i>Cancer Science</i> , 2022, 113, 287-296. | 3.9 | 10 |
| 23 | Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced non-small cell lung cancer with bone metastases. <i>Anticancer Research</i> , 2012, 32, 4131-5. | 1.1 | 8 |
| 24 | Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 565-572. | 2.3 | 7 |
| 25 | Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting. <i>Anticancer Research</i> , 2017, 37, 1507-1514. | 1.1 | 7 |
| 26 | Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C. <i>Targeted Oncology</i> , 2021, 16, 339-355. | 3.6 | 6 |
| 27 | Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. <i>Lung Cancer</i> , 2021, 159, 162-170. | 2.0 | 6 |
| 28 | Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100405. | 1.7 | 6 |
| 29 | Antiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. <i>European Journal of Cancer</i> , 2022, 166, 112-125. | 2.8 | 4 |
| 30 | Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy. <i>Lung Cancer</i> , 2007, 58, 73-79. | 2.0 | 3 |
| 31 | High proportion of tumor necrosis predicts poor survival in surgically resected high-grade neuroendocrine carcinoma of the lung. <i>Lung Cancer</i> , 2021, 157, 1-8. | 2.0 | 3 |